MRVI MARAVAI LIFESCIENCES HOLDINGS INC
Health Care · Russell 2000
Next earnings: not announced yet
What 11 analyst firms say about MARAVAI LIFESCIENCES HOLDINGS INC: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
11 rated views · 12 analyst/firm records · 11 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Average target is not above the current price
- Russell 2000 · Safest consensus · 6MNot scored · Average target is not above the current price
Recent analyst activity · last 90 days
Our tracked history has 3 reports on MRVI from 3 analyst firms in the last 90 days (11 firms in the past year).
Comparing each firm's latest target with its previous one: 2 have their first observed target in the past year.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Craig-Hallum | Matthew G Hewitt | Buy | 7 Aug 2026 | 7.00 USD |
| Deutsche Bank | Unnamed analyst | Buy | 8 May 2026 | 6.00 USD |
| Guggenheim | Subbu Nambi | Hold | 1 Jun 2026 | — |
| Jefferies | Matthew Stanton | Buy | 14 Jul 2026 | 7.00 USD |
| KeyBanc Capital Markets | Paul Knight | Hold | 3 Aug 2026 | — |
| TD Cowen | Brendan Smith | Buy | 5 Oct 2026 | 9.00 USD |
| UBS | Dan Brennan | Hold | 9 Sep 2026 | 8.00 USD |
| UBS | Doug Schenkel | Hold | 9 Sep 2026 | 8.00 USD |
| Weiss Ratings | Unnamed analyst | — | 26 Aug 2026 | — |
| Wells Fargo | Evan Stampler | Buy | 7 Aug 2026 | 6.50 USD |
| William Blair | Matt Larew | Hold | 7 Aug 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:09 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.